SCHEMBL27489013

SCHEMBL27489013

NNC(=O)c1ccccc1S(=O)(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 5/20 0.73
CA1 P00915 4/20 0.73
CA2 P00918 4/20 0.73
CTSD P07339 2/20 0.49
DDX3X O00571 2/20 0.48
ALDH1A1 P00352 2/20 0.47
P2RX7 Q99572 1/20 0.47
BCAT2 O15382 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MITF O75030 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
NCOA1 Q15788 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
CA5A P35218 1/20 0.43
MMP1 P03956 2/20 0.42
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27805191 0.85 CA1 (1.00) CA9CA1CA2CTSDALDH1A1
SCHEMBL1127863 0.83 CA1 (0.71) CA9CA1CA2CTSDALDH1A1
SCHEMBL14761512 0.83 CA9 (0.71) CA9CA1CA2CTSDALDH1A1
SCHEMBL11177249 0.81 CA1 (0.49) CA9CA1CA2DDX3XBCAT2
SCHEMBL4805233 0.81 POLB (0.58) CA9CA1CA2DDX3XBCAT2
SCHEMBL8609710 0.80 CA1 (0.67) CA9CA1CA2CTSDALDH1A1
SCHEMBL13972822 0.80 CA9 (0.49) CA9CA1CA2DDX3XBCAT2
SCHEMBL1508326 0.79 KEAP1 (0.54) CA9CA1CA2DDX3XBCAT2
SCHEMBL21424612 0.79 CA1 (0.47) CA9CA1CA2DDX3XALDH1A1
SCHEMBL239328 0.79 CTSD (0.63) CA9CA1CA2CTSDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1429108-A Phosphate transport inhibitors SMITHKLINE BEECHAM CORP (US) 2003-07-09 CN claimed
CN-118852324-A Albumin binding products of auristatin E derivatives 拉德克斯公司 2024-10-29 CN disclosed
CN-111712511-B Albumin binding products of auristatin E derivatives 拉德克斯公司 2024-07-16 CN disclosed
EP-3717503-B1 ALBUMIN-BINDING PRODRUGS OF AURISTATIN E DERIVATIVES LADRX CORP (US) 2023-11-08 EP disclosed
US-11377473-B2 Albumin-binding prodrugs of auristatin E derivatives CENTURION BIOPHARMA CORPORATION (US) 2022-07-05 US disclosed
CN-1211384-C Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agent UPJOHN CO (US) 2005-07-20 CN disclosed
CN-1429108-A Phosphate transport inhibitors SMITHKLINE BEECHAM CORP (US) 2003-07-09 CN disclosed
CN-1261889-A Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agent UPJOHN CO (US) 2000-08-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377473-B2 Albumin-binding prodrugs of auristatin E derivatives ALB, AURKB, AURKA CA9 1497/4885CA1 981/4885CA2 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.